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EVERY LIKE IS NOT THE
SAME
To the Editor:
We read with great interest the
report about the late outcome of de-
cellularized aortic homografts
(DAH) used for aortic valve replace-
ment (AVR) in middle-aged adults, one-quarter of patients
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Helder et al1 described a trend for higher reoperation
rates in DAH versus standard cryopreserved homografts
and comparable histological modes of degeneration. We,ter implantation of an 18-mm fresh, noncryopreserve
observed, aortic valve ring and effective orifice area
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The Journal of Thoracic and Caras the investigators of a European-wide prospective trial
on DAH for AVR, however, felt that the title may be some-
what misleading, as every like is not the same.
Decellularization of biological matrices can be per-
formed by different protocols and results may not neces-
sarily be comparable, as mechanical properties of the
matrix structure are crucial for durability. Preservation of
the matrix structure is also essential for recellularization.
Homografts in the report by Helder et al1 have been cryo-
preserved and radiated before implantation. Both of these
procedures have been demonstrated to affect the ultrastruc-
ture.2 In contrast, the ARISE trial is evaluating fresh, non-
cryopreserved DAH for AVR.
Previous work has shown auspicious early results in a
limited cohort of children and young adults (n ¼ 69,
mean age 19.7  14.6 years, mean follow-up
2.0  1.8 years) prone to rapid degeneration and
regeneration.3,4
Anecdotal experience from some of our grafts has been
favorable. Figure 1 (and the Videos 1-3) show the excellent
function of such a homograft 8 years after implantation in
an 8-year-old girl without any evidence of degeneration ord decellularized aortic homograft in an 8-year-old girl. Within 8 years, no
increased.
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VIDEO 2. Orthogonal cine view of the aortic valve showing normal open-
ing and closure. Video available at: http://www.jtcvsonline.org/article/
S0022-S0022-5223(17)30180-0/addons.
Video clip is available online.





calcification. We also did not see calcification in a histolog-
ical examination of an explanted aortic valve 4.5 years after
implantation in an 8-week-old infant. Recellularization by
noninflammatory recipient cells was seen in this patient,
where the aortic valve developed regurgitation potentially
related to a recurrent subvalvular stenosis.3
In another infant, 4 months after implantation of non-
valved DAH in a staged Norwood procedure, adequate re-
cellularization was found in the outer two-thirds of the
circumference, underlining the importance of the adventi-
tial space.5
Good long-term performance of DAH necessitates inte-
gration of the graft and regeneration by recellularization,
which, however, is much more likely to occur when there
is a near-normal anatomic position and blood flow. Even a
normal heart valvewill degenerate in pathological flow con-
ditions due to limited regenerative capacity in such situa-
tion. One, to our understanding, cannot expect a
decellularized homograft to perform even better and weVIDEO1. Coronal cine view of the LVOT showing good integration of the
decellularized homograft and normal left ventricular function 8 years after
implantation in an 8-year-old girl. Video available at: http://www.
jtcvsonline.org/article/S0022-S0022-5223(17)30180-0/addons.
1554 The Journal of Thoracic and Cardiovascular Surtherefore aim for almost laminar flow conditions and we
also aim to avoid obstruction for recellularization, such as
tissue-glue, foreign material, or wrapping procedures.VIDEO 3. Phase-contrast flow imaging of the aortic valve demonstrating
complete competence and unobstructed flow. Video available at: http://
www.jtcvsonline.org/article/S0022-S0022-5223(17)30180-0/addons.
gery c June 2017





Acute endocarditis cannot be viewed as an ideal setting
for recellularization by regular recipient cells. The open
matrix may even allow for bacterial invasion, thereby
prompting infiltration of immune competent cells and in-
flammatory cascades leading to early calcification. We,
therefore, do not recommend the use of decellularized
matrices in the setting of acute endocarditis, even though
the endocarditis susceptibility of DAH at this point appears
low.
The ARISE investigators strongly agree with the
editorial comments made by Dr Bando proposing late
outcome studies on DAH.6 In fact, prospective long-term
follow-up is part of both investigator-initiated European-
wide trials on fresh decellularized allografts for pulmonary
and aortic valve replacement7,8 to answer the question of
whether such homografts are really superior, or just
fashion.9
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Reply to the Editor:
Cardiovascular surgeons con-
tinue to innovate materials. Artificial
vascular grafts such as polytetra-
fluoroethylene and Dacron have a
long history of ‘‘adequacy’’ with acknowledged limits. Bio-diovascular Surgeryprosthetic grafts have offered a dense forest of options. Cur-
rent efforts include cryopreserved homografts, bovine
jugular grafts (some with bioprosthetic valves), harvested
umbilical vein, and various types of decellularized vascular
grafts. Each has potential advantages. Tissue-engineered
approaches are starting to show promise. With that many
options, it is obvious there is not a perfect choice. In thisc Volume 153, Number 6 1555
